Loading...
•
Sep 30, 2024
Gilead Sciences Q3 2024 Earnings Report
Gilead Sciences reported strong Q3 2024 results with revenue growth and increased guidance.
Key Takeaways
Gilead Sciences announced strong third quarter 2024 financial results, with a 7% increase in total revenue to $7.5 billion. The company is increasing its full-year revenue, operating income, and earnings per share guidance.
Total revenue increased 7% year-over-year to $7.5 billion.
Biktarvy sales increased 13% year-over-year to $3.5 billion.
Oncology sales increased 6% year-over-year to $816 million.
Diluted EPS was $1.00, while non-GAAP diluted EPS was $2.02.
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
For the full-year 2024, Gilead expects product sales between $27.8 billion and $28.1 billion, and non-GAAP diluted EPS between $4.25 and $4.45.
Positive Outlook
- Product sales are expected to be between $27.8 billion and $28.1 billion.
- Product sales, excluding Veklury, are expected to be between $26.0 billion and $26.3 billion.
- Veklury sales are expected to be $1.8 billion.
- Diluted EPS is expected to be between $0.05 and $0.25.
- Non-GAAP diluted EPS is expected to be between $4.25 and $4.45.